Beam Therapeutics
BEAM
218 hedge funds and large institutions have $2.59B invested in Beam Therapeutics in 2025 Q3 according to their latest regulatory filings, with 40 funds opening new positions, 78 increasing their positions, 54 reducing their positions, and 35 closing their positions.
59% more call options, than puts
Call options by funds: $23.9M | Put options by funds: $15M
44% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 54
40% more capital invested
Capital invested by funds: $1.84B → $2.59B (+$743M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
14% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 35
1% more funds holding
Funds holding: 216 → 218 (+2)
2.41% less ownership
Funds ownership: 107.77% → 105.36% (-2.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$43.6M |
| 2 |
CGH
Contrarius Group Holdings
Hamilton,
Bermuda
|
+$30.5M |
| 3 |
UBS AM
Chicago,
Illinois
|
+$23.3M |
| 4 |
State Street
Boston,
Massachusetts
|
+$7.37M |
| 5 |
IEFM
IQ EQ Fund Management
Dublin 2,
Ireland
|
+$3.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$46.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$25.2M |
| 3 |
Morgan Stanley
New York
|
-$13.2M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$10.4M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$9.21M |
BEAM Hedge Fund Activity: Q3 2025 in Review
218 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Beam Therapeutics (BEAM) for Q3 2025, worth a combined $2.59B — up 40% from $1.84B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new BEAM positions and 35 closed out — a net gain of 5 holders — while 78 added to existing stakes and 54 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $43.6M. The largest seller was Citadel Advisors, exiting entirely with an estimated $46.5M sold.
- 218 institutional investors held Beam Therapeutics (BEAM) as of Q3 2025, up from 216 in Q2 2025.
- Funds reported $2.59B of Beam Therapeutics stock for Q3 2025, up 40% quarter-over-quarter.
- 40 funds opened new Beam Therapeutics positions in Q3 2025 and 35 closed out, a net change of +5 holders.
- The largest Beam Therapeutics buyer in Q3 2025 was ARK Investment Management, an estimated $43.6M added.
- The largest Beam Therapeutics seller in Q3 2025 was Citadel Advisors, an estimated $46.5M sold.
Based on aggregated 13F filings for Q3 2025.